Cholangiocarcinoma Excellence Forum

Cholangiocarcinoma

Excellence Forum

Videos

Outcomes of Liver Transplantation for Perihilar Cholangiocarcinoma: New Standard of Care?

11/23/2022

Julie Heimbach, MD, discusses a benchmark study that investigated outcomes of patients who received neoadjuvant chemoradiotherapy followed by liver transplantation for perihilar cholangiocarcinoma.

Julie Heimbach, MD, discusses a...

11/23/2022

Oncology

TIm Pawlik, MD, PhD, MPH, Wexner Medical Center

Videos

Researchers Develop Dynamic Prognostic Model for Patients With Intrahepatic Cholangiocarcinoma Undergoing Curative Resection

11/16/2022

Tim Pawlik, MD, explains how he and colleagues used landmark analysis to develop a prognostic model that provides a more dynamic prediction of long-term outcomes for patients undergoing curative-intent surgery for intrahepatic...

Tim Pawlik, MD, explains how he...

11/16/2022

Oncology

Lipika Goyal, MD, Stanford Cancer Center

Videos

Futibatinib Receives FDA Approval for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions and Rearrangements

10/31/2022

Lipika Goyal, MD, shares her insight about the recent FDA approval of futibatinib for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements and discusses findings from the FOENIX-CCA2 trial, which led to the approval.

Lipika Goyal, MD, shares her...

10/31/2022

Oncology

Quiz

True or False: In the phase 2 FIDES-01 study, derazantinib was found to have a comparable toxicity profile to other FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib.

10/21/2022

In the phase 2 FIDES-01 study, was derazantinib found to have a comparable toxicity profile to other small molecule, FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib?

In the phase 2 FIDES-01 study,...

10/21/2022

Oncology

Mitesh Borad, MD, Mayo Clinic Cancer Center

Videos

Derazantinib Demonstrates Efficacy, Tolerability for Intrahepatic Cholangiocarcinoma With FGFR2 Aberrations

10/17/2022

Mitesh Borad, MD, reviews results from a pivotal phase 2 trial investigating derazantinib in chemotherapy-exposed patients with intrahepatic cholangiocarcinoma and FGFR2 fusions, mutations, or amplifications.

Mitesh Borad, MD, reviews...

10/17/2022

Oncology

Quiz

Quiz: Durvalumab Added to Gemcitabine-Cisplatin for Biliary Tract Cancers

09/02/2022

In the TOPAZ-1 trial which determined whether the addition of durvalumab to gemcitabine-cisplatin chemotherapy conferred a survival benefit for patients with advanced or metastatic biliary tract cancers, which primary tumor location saw...

In the TOPAZ-1 trial which...

09/02/2022

Oncology

Rachna Schroff, MD, University of Arizona Cancer Center

Videos

Developments in Novel and Targeted Therapies for Biliary Tract Cancers

09/01/2022

Rachna Shroff, MD, highlights recent developments in the treatment of cholangiocarcinoma, including updates in novel and targeted therapies, during her presentation at the Great Debates and Updates in Gastrointestinal Malignancies meeting.

Rachna Shroff, MD, highlights...

09/01/2022

Oncology

Podcasts

BRCAness May Predict Response to Platinum-Based Chemotherapy in Intrahepatic Cholangiocarcinoma

07/29/2022

Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.

Margherita Rimini, MD, discusses...

07/29/2022

Oncology

Ruth He, MD, Lombardi Comprehensive Cancer Center

Podcasts

Durvalumab Plus Chemotherapy Improves Outcomes in Biliary Tract Cancer Across Primary Tumor Locations

07/22/2022

Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...

Ruth He, MD, discusses findings...

07/22/2022

Oncology

Arndt Vogel, MD, Hannover Medical School

Podcasts

Pemigatinib for Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

07/14/2022

Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.

Arndt Vogel, MD, shares results...

07/14/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology